{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:44:09Z","timestamp":1792701849824,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euroneuro.2025.08.580","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:07:00Z","timestamp":1756379220000},"page":"4-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5203","authenticated-orcid":false,"given":"Mikkel","family":"H\u00f8jlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-1099","authenticated-orcid":false,"given":"Christiane","family":"Gasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Fink-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"K\u00f6hler-Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.08.580_bib0001","unstructured":"Baandrup, L., Lublin, H., Nordentoft, M., Peacock, L., S\u00f8rensen, J., Andersen, S.E., Glenth\u00f8j, B., 2011. Antipsykotisk polyfarmaci i behandlingen af skizofreni \u2013 en medicinsk teknologivurdering [Antipsychotic polypharmacy in the treatment of schizophrenia - a health technology assessment]."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0006","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0007","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice","volume":"35","author":"Correll","year":"2012","journal-title":"Psychiat. Clinics of North Am."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0009","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euroneuro.2025.05.003","article-title":"Comparative mortality risk of antipsychotics in 41,695 patients with schizophrenia: an 11-year population-based cohort study in Hong Kong","volume":"96","author":"Fang","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0012","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0013","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19ac13118","article-title":"Antipsychotic polypharmacy in schizophrenia: why not?","volume":"81","author":"Guinart","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211046765","article-title":"Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial","volume":"11","author":"Gupta","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.760181","article-title":"The more, the merrier\u2026? Antipsychotic polypharmacy treatment strategies in schizophrenia from a pharmacology perspective","volume":"12","author":"Hjorth","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0016","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis","volume":"11","author":"H\u00f8jlund","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2024.06.001","article-title":"Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: a systematic review and meta-analysis of randomized clinical trials","volume":"270","author":"K\u00f6hler-Forsberg","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0019","unstructured":"Leucht, S., Arango, C., Fleischhacker, W.W., Kapur, S., Stroup, S., Van Os, J., Correll, C.U., 2013. CINP Schizophrenia Guideline. International College of Neuropsychopharmacology (CINP)."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0022","unstructured":"Medicinr\u00e5det, 2020. Medicinr\u00e5dets behandlingsvejledning vedr\u00f8rende antipsykotika til behandling af psykotiske tilstande hos voksne [Guideline for treatment with antipsychotics in psychotic disorders in adults]."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0023","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"AJP"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1403494810395825","article-title":"The Danish Psychiatric Central Research Register","volume":"39","author":"Mors","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0026","article-title":"Data resource Profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0027","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bcpt.13772","article-title":"Free-of-charge dispensing of antipsychotics for schizophrenia in Denmark: impact on the nationwide prescription registry and redemption of somatic medications","volume":"131","author":"Rohde","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0028","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.euroneuro.2015.04.027","article-title":"Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study","volume":"25","author":"Sneider","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0029","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1038\/s41380-023-02298-3","article-title":"An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbae058","article-title":"Antipsychotic use and risk of breast cancer in women with severe mental illness: replication of a nationwide nested case\u2013Control database study","author":"Solmi","year":"2024","journal-title":"Schizophrenia Bulletin sbae058"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0032","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/schbul\/sbab087","article-title":"Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study","volume":"48","author":"Solmi","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0033","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0034","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.20220446","article-title":"Safety of antipsychotic polypharmacy versus monotherapy in a nationwide cohort of 61,889 patients with schizophrenia","volume":"180","author":"Taipale","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0036","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods \u2013 a second generation method (PRE2DUP)","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC. Med. Inform. Decis. Mak."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0037","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S003329170700147X","article-title":"The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards \u2013 a cluster randomized controlled trial","volume":"38","author":"Thompson","year":"2008","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0038","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0039","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(24)00367-5","article-title":"The challenges of antipsychotic polypharmacy","volume":"11","author":"Tiihonen","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/wps.21316","article-title":"Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts","volume":"24","author":"Tiihonen","year":"2025","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0042","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0043","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","article-title":"Clozapine combination and augmentation strategies in patients with Schizophrenia \u2014Recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group","volume":"46","author":"Wagner","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpsychires.2018.08.002","article-title":"ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"105","author":"Wang","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2025.08.580_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103375","article-title":"Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment","volume":"79","author":"Yeh","year":"2023","journal-title":"Asian J. Psychiatr."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25007412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25007412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:11:36Z","timestamp":1760742696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25007412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"alternative-id":["S0924977X25007412"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.08.580","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.08.580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}